Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

FDA Approves Juvéderm Vollure XC for Laugh Lines, Notes Dr. F. Victor Rueckl of Lakes Dermatology
  • USA - English


News provided by

Lakes Dermatology

Mar 30, 2017, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Allergan's Newest Introduction: VollureXC available at Lakes Dermatology
Allergan's Newest Introduction: VollureXC available at Lakes Dermatology

This new treatment adds subtle volume for the correction of moderate to severe facial wrinkles and folds to provide a more youthful look that is also highly natural.

Post this

Las Vegas, Nevada (PRWEB) March 30, 2017 -- The old adage of putting one's best face forward has some wisdom behind it. An individual's face is an important aspect of how the world views them, and many people want to present a face that looks as young and as healthy as possible. While the skin itself is the largest organ of the human body, coming in at roughly 18.5 square feet, the face is what captures the most attention. (1) Sonnets are written about the rosy blush in one's cheeks or the fullness of the lips, not the texture of one's knees or elbows. However, many wrinkles and lines appear as one gets older, especially around the mouth. Many people seek to revitalize their appearance by having a dermal filler injected to plump up the skin and restore the appearance of a younger visage. While there are a good number of fillers on the market, licensed dermatologists, such as Dr. F. Victor Rueckl of Lakes Dermatology, are excited about the recent FDA approval of Juvéderm Vollure XC for the treatment of moderate to severe facial wrinkles, such as the laugh lines. Vollure XC is known as Volift in other countries.

The approval of Juvéderm Vollure XC by the FDA is good news for those seeking a minimally-invasive procedure to deal with those pesky laugh lines. The use of dermal fillers has proven extremely popular with those seeking to enhance their appearance and look younger by smoothing out and reducing wrinkles. The American Society of Plastic Surgeons notes that the application of soft tissue fillers was the second most popular minimally-invasive procedure in 2016, with a grand total of 2.6 million procedures being performed. (2) One of the problem areas that people want work done upon are the nasolabial folds, or more commonly known as the laugh lines. These lines become more pronounced as one ages as the ligaments around the mouth and chin loosen, which then allows the fatty tissue in the cheeks to sag. Medical professionals, such as Dr. F. Victor Rueckl of Lakes Dermatology of Las Vegas, know that many older individuals, especially women, are not happy with the appearance of their laugh lines. Studies have shown that most women over the age of thirty-five were not happy with their laugh lines, and a Canadian study in 2013 showed that one in five women, aged thirty to sixty, were bothered by their laugh lines as they felt that their nasolabial folds made them look older than what the women actually were. (3)

The FDA has recently approved the use of Juvéderm Vollure XC to treat moderate to severe facial wrinkles and folds in adults older than twenty-one years. Allergan, the maker of Juvéderm Vollure XC, ran a clinical trial that showed the long-lasting effects of the hyaluronic acid (HA) dermal filler. In the trial, 59% of patients saw improvement in their laugh lines for up to eighteen months, and a full 82% of patients said that they were very satisfied with the results at six month. At eighteen months, the percentage of patients who expressed being very satisfied was 68%, which is a remarkable number. (4) Experienced dermatologists, such as Dr. F. Victor Rueckl of Lakes Dermatology, are happy to have another tool at their disposal to use on behalf of their patients. They also note that Juvéderm Vollure XC is the first and only FDA-approved HA filler for moderate to severe facial wrinkles that lasts up to a full eighteen months.

Dr. F. Victor Rueckl of Lakes Dermatology in Las Vegas says, "I can't wait to begin using Juvéderm Vollure XC to help improve the appearance of my patients by greatly decreasing the visibility of those pesky laugh lines we all get as we get older. This new treatment adds subtle volume for the correction of moderate to severe facial wrinkles and folds to provide a more youthful look that is also highly natural. Juvéderm Vollure XC is a custom engineered injectable gel that truly delivers immediate and long-lasting results that my patients are going to love. This new FDA-approved dermal filler lasts for such a long time due to the fact that it has been formulated with Allergan's proprietary Vycross technology, which blends different molecular weights of hyaluronic acid, thus contributing to the gel's duration. Clinical trials have shown the safety and effectiveness of this new treatment, not to mention the very high rate of patient satisfaction. As an AMFAST trainer, I will be able to begin offering Juvéderm Vollure XC to my clients as soon as it is commercially available. As with any cosmetic procedure, there can be some side effects that are experienced. The most common side effects associated with Juvéderm Vollure XC are redness at the injection site, swelling, tenderness, pain, firmness, bruising, itching, lumps/bumps, and discoloration. These side effects usually cleared up within seven days during the clinical trial." (5)

Individuals now have an FDA-approved treatment for those pesky laugh lines that will last for up to eighteen months in the form of Juvéderm Vollure XC. Licensed medical professionals, such as Dr. F. Victor Rueckl of Lakes Dermatology, are eager to begin using this new dermal filler to help their patients look younger and feel better. Clinical trials have proven the effectiveness of Juvéderm Vollure XC as well as its lengthy duration of up to eighteen months.

References:
1) http://www.everydayhealth.com/news/10-amazing-facts-about-skin/
2) https://www.plasticsurgery.org/news/press-releases/new-plastic-surgery-statistics-reveal-focus-on-face-and-fat
3) http://theskiny.com/juvederm-volift-for-smile-lines/
4) http://www.medscape.com/viewarticle/877451?nlid=113515_3901&src=wnl_newsalrt_170320_MSCPEDIT&uac=29196BJ&impID=1312014&faf=1
5) Quote from Dr. F. Victor Rueckl, dermatologist at Lakes Dermatology

Katie Rueckl, Lakes Dermatology, http://www.lakesdermatology.com, +1 9703890932, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.